Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia

Joshua A. Sonnen, Kathleen S. Montine, Joseph Quinn, John C S Breitner, Thomas J. Montine

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Given the magnitude of the public health problem of dementia in the elderly, there is a pressing need for research, development, and timely application of biomarkers that will identify latent and prodromal illness as well as dementia. Although identification of risk factors and neuroimaging measures will remain key to these efforts, this review focuses on recent progress in the discovery, validation, and standardization of cerebrospinal fluid (CSF) biomarkers, small molecules and macromolecules whose CSF concentration can aid in diagnosis at different stages of disease as well as in assessment of disease progression and response to therapeutics. A multimodal approach that brings independent information from risk factor assessment, neuroimaging, and biomarkers may soon guide physicians in the early diagnosis and management of cognitive impairment in the elderly.

Original languageEnglish (US)
Pages (from-to)301-309
Number of pages9
JournalJournal of Alzheimer's Disease
Volume19
Issue number1
DOIs
StatePublished - 2010

Fingerprint

Cerebrospinal Fluid
Dementia
Biomarkers
Neuroimaging
Disease Progression
Early Diagnosis
Public Health
Physicians
Research
Cognitive Dysfunction
Therapeutics

Keywords

  • Alzheimer's disease
  • Biomarkers
  • Cerebrospinal fluid
  • Lewy body disease
  • Vascular cognitive impairment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. / Sonnen, Joshua A.; Montine, Kathleen S.; Quinn, Joseph; Breitner, John C S; Montine, Thomas J.

In: Journal of Alzheimer's Disease, Vol. 19, No. 1, 2010, p. 301-309.

Research output: Contribution to journalArticle

Sonnen, Joshua A. ; Montine, Kathleen S. ; Quinn, Joseph ; Breitner, John C S ; Montine, Thomas J. / Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia. In: Journal of Alzheimer's Disease. 2010 ; Vol. 19, No. 1. pp. 301-309.
@article{16f39baca9af4d4e8796448cea024e5d,
title = "Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia",
abstract = "Given the magnitude of the public health problem of dementia in the elderly, there is a pressing need for research, development, and timely application of biomarkers that will identify latent and prodromal illness as well as dementia. Although identification of risk factors and neuroimaging measures will remain key to these efforts, this review focuses on recent progress in the discovery, validation, and standardization of cerebrospinal fluid (CSF) biomarkers, small molecules and macromolecules whose CSF concentration can aid in diagnosis at different stages of disease as well as in assessment of disease progression and response to therapeutics. A multimodal approach that brings independent information from risk factor assessment, neuroimaging, and biomarkers may soon guide physicians in the early diagnosis and management of cognitive impairment in the elderly.",
keywords = "Alzheimer's disease, Biomarkers, Cerebrospinal fluid, Lewy body disease, Vascular cognitive impairment",
author = "Sonnen, {Joshua A.} and Montine, {Kathleen S.} and Joseph Quinn and Breitner, {John C S} and Montine, {Thomas J.}",
year = "2010",
doi = "10.3233/JAD-2010-1236",
language = "English (US)",
volume = "19",
pages = "301--309",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Cerebrospinal fluid biomarkers in mild cognitive impairment and dementia

AU - Sonnen, Joshua A.

AU - Montine, Kathleen S.

AU - Quinn, Joseph

AU - Breitner, John C S

AU - Montine, Thomas J.

PY - 2010

Y1 - 2010

N2 - Given the magnitude of the public health problem of dementia in the elderly, there is a pressing need for research, development, and timely application of biomarkers that will identify latent and prodromal illness as well as dementia. Although identification of risk factors and neuroimaging measures will remain key to these efforts, this review focuses on recent progress in the discovery, validation, and standardization of cerebrospinal fluid (CSF) biomarkers, small molecules and macromolecules whose CSF concentration can aid in diagnosis at different stages of disease as well as in assessment of disease progression and response to therapeutics. A multimodal approach that brings independent information from risk factor assessment, neuroimaging, and biomarkers may soon guide physicians in the early diagnosis and management of cognitive impairment in the elderly.

AB - Given the magnitude of the public health problem of dementia in the elderly, there is a pressing need for research, development, and timely application of biomarkers that will identify latent and prodromal illness as well as dementia. Although identification of risk factors and neuroimaging measures will remain key to these efforts, this review focuses on recent progress in the discovery, validation, and standardization of cerebrospinal fluid (CSF) biomarkers, small molecules and macromolecules whose CSF concentration can aid in diagnosis at different stages of disease as well as in assessment of disease progression and response to therapeutics. A multimodal approach that brings independent information from risk factor assessment, neuroimaging, and biomarkers may soon guide physicians in the early diagnosis and management of cognitive impairment in the elderly.

KW - Alzheimer's disease

KW - Biomarkers

KW - Cerebrospinal fluid

KW - Lewy body disease

KW - Vascular cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=75149131762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149131762&partnerID=8YFLogxK

U2 - 10.3233/JAD-2010-1236

DO - 10.3233/JAD-2010-1236

M3 - Article

C2 - 20061646

AN - SCOPUS:75149131762

VL - 19

SP - 301

EP - 309

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -